Frontiers in Cellular and Infection Microbiology (Feb 2022)

Diagnostic Performance of Seven Commercial COVID-19 Serology Tests Available in South America

  • Ismar A. Rivera-Olivero,
  • Aquiles R. Henríquez-Trujillo,
  • Nikolaos C. Kyriakidis,
  • Esteban Ortiz-Prado,
  • Juan Carlos Laglaguano,
  • Alexander Paolo Vallejo-Janeta,
  • Tannya Lozada,
  • Miguel Angel Garcia-Bereguiain,
  • UDLA COVID-19 team

DOI
https://doi.org/10.3389/fcimb.2022.787987
Journal volume & issue
Vol. 12

Abstract

Read online

BackgroundAlthough RT-qPCR remains the gold-standard for COVID-19 diagnosis, anti-SARS-CoV-2 serology-based assays have been widely used during 2020 as an alternative for individual and mass testing, and are currently used for seroprevalence studies.ObjectiveTo study the clinical performance of seven commercial serological tests for COVID-19 diagnosis available in South America.MethodsWe conducted a blind evaluation of five lateral-flow immunoassays (LFIA) and two enzyme-linked immunosorbent assays (ELISAs) for detecting anti-SARS-CoV-2 antibodies.ResultsWe found no statistically significant differences among ELISA kits and LFIAs for anti-SARS-CoV-2 IgG sensitivity (values ranging from 76.4% to 83.5%) and specificity (100% for the seven serological assays). For anti-SARS-CoV-2 IgM, the five LFIAs have a significantly higher sensitivity for samples collected 15 days after the first time RT-qPCR positive test, with values ranging from 47.1% to 88.2%; moreover, the specificity varied from 85% to 100%, but the only LFIA brand with a 100% specificity had the lowest sensitivity.ConclusionThe diagnostic performance of the seven serological tests was acceptable for the seven brands tested for anti-SARS-CoV-2 IgG detection for seroprevalence screening purposes. On the other hand, our results show the lack of accuracy of anti-SARS-CoV-2 IgM detection in LFIAs as a tool for SARS-CoV-2 acute-phase infection diagnosis.

Keywords